CTTI would like to welcome newest members Rexahn Pharmaceuticals and Mark Krueger & Associates, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for the treatment of cancer. Chief Medical Officer Ely Benaim will represent this organization on CTTI’s Steering Committee.

Mark Krueger & Associates, Inc. is a consulting firm focused on healthcare constituency relations. Senior Vice President Ellen Coleman will represent this organization on CTTI’s Steering Committee.

CTTI engages all stakeholders to collaboratively improve the quality and efficiency of the clinical trials enterprise. For more information about the diverse representation of CTTI’s membership, click here.